205 related articles for article (PubMed ID: 29530432)
1. High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer.
Fang P; Jiang W; Davuluri R; Xu C; Krishnan S; Mohan R; Koong AC; Hsu CC; Lin SH
Radiother Oncol; 2018 Sep; 128(3):584-590. PubMed ID: 29530432
[TBL] [Abstract][Full Text] [Related]
2. Lymphocyte nadir predicts tumor response and survival in locally advanced rectal cancer after neoadjuvant chemoradiotherapy: Immunologic relevance.
Liu H; Wang H; Wu J; Wang Y; Zhao L; Li G; Zhou M
Radiother Oncol; 2019 Feb; 131():52-59. PubMed ID: 30773187
[TBL] [Abstract][Full Text] [Related]
3. Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy.
Davuluri R; Jiang W; Fang P; Xu C; Komaki R; Gomez DR; Welsh J; Cox JD; Crane CH; Hsu CC; Lin SH
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):128-135. PubMed ID: 28816138
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort.
Qi WX; Wang X; Li C; Li S; Li H; Xu F; Chen J; Zhao S; Li H
Thorac Cancer; 2023 Jun; 14(17):1556-1566. PubMed ID: 37089116
[TBL] [Abstract][Full Text] [Related]
5. Association Between Lymphopenia and Survival Outcomes in Esophageal Carcinoma Patients Receiving Combined Immunotherapy and Chemoradiotherapy.
Cheng X; Chen B; Wang S; Zhang J; Zhu J; Liu M; Liu S; Xi M
Oncologist; 2023 Aug; 28(8):e606-e616. PubMed ID: 37061835
[TBL] [Abstract][Full Text] [Related]
6. Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma Incorporating Hematological Biomarkers.
Wu Y; Chen J; Zhao L; Li Q; Zhu J; Yang H; Guo S; Xi M
Cancer Res Treat; 2021 Jan; 53(1):172-183. PubMed ID: 32898941
[TBL] [Abstract][Full Text] [Related]
7. The relationship of lymphocyte recovery and prognosis of esophageal cancer patients with severe radiation-induced lymphopenia after chemoradiation therapy.
Deng W; Xu C; Liu A; van Rossum PSN; Deng W; Liao Z; Koong AC; Mohan R; Lin SH
Radiother Oncol; 2019 Apr; 133():9-15. PubMed ID: 30935587
[TBL] [Abstract][Full Text] [Related]
8. Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy.
Shiraishi Y; Fang P; Xu C; Song J; Krishnan S; Koay EJ; Mehran RJ; Hofstetter WL; Blum-Murphy M; Ajani JA; Komaki R; Minsky B; Mohan R; Hsu CC; Hobbs BP; Lin SH
Radiother Oncol; 2018 Jul; 128(1):154-160. PubMed ID: 29248170
[TBL] [Abstract][Full Text] [Related]
9. Prediction of Response to Neoadjuvant Chemotherapy and Radiation Therapy with Baseline and Restaging
Beukinga RJ; Hulshoff JB; Mul VEM; Noordzij W; Kats-Ugurlu G; Slart RHJA; Plukker JTM
Radiology; 2018 Jun; 287(3):983-992. PubMed ID: 29533721
[TBL] [Abstract][Full Text] [Related]
10. Influence of tumor response and treatment schedule on the distribution of tumor recurrence in esophageal cancer patients treated with neoadjuvant chemoradiotherapy.
Jipping KM; Hulshoff JB; van Amerongen EA; Bright TI; Watson DI; Plukker JTM
J Surg Oncol; 2017 Dec; 116(8):1096-1102. PubMed ID: 28853141
[TBL] [Abstract][Full Text] [Related]
11. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant versus definitive chemoradiation in patients with squamous cell carcinoma of the esophagus.
Münch S; Pigorsch SU; Devečka M; Dapper H; Feith M; Friess H; Weichert W; Jesinghaus M; Braren R; Combs SE; Habermehl D
Radiat Oncol; 2019 Apr; 14(1):66. PubMed ID: 30992022
[TBL] [Abstract][Full Text] [Related]
13. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study.
Borggreve AS; Mook S; Verheij M; Mul VEM; Bergman JJ; Bartels-Rutten A; Ter Beek LC; Beets-Tan RGH; Bennink RJ; van Berge Henegouwen MI; Brosens LAA; Defize IL; van Dieren JM; Dijkstra H; van Hillegersberg R; Hulshof MC; van Laarhoven HWM; Lam MGEH; van Lier ALHMW; Muijs CT; Nagengast WB; Nederveen AJ; Noordzij W; Plukker JTM; van Rossum PSN; Ruurda JP; van Sandick JW; Weusten BLAM; Voncken FEM; Yakar D; Meijer GJ;
BMC Cancer; 2018 Oct; 18(1):1006. PubMed ID: 30342494
[TBL] [Abstract][Full Text] [Related]
14. Development of a nomogram for the prediction of pathological complete response after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Chao YK; Chang HK; Tseng CK; Liu YH; Wen YW
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27868287
[TBL] [Abstract][Full Text] [Related]
15. Effects of Neoadjuvant Chemoradiotherapy on Pathological TNM Stage and Their Prognostic Significance for Surgically-treated Esophageal Squamous Cell Carcinoma.
Hamai Y; Hihara J; Emi M; Furukawa T; Ibuki Y; Yamakita I; Kurokawa T; Okada M
Anticancer Res; 2017 Oct; 37(10):5639-5646. PubMed ID: 28982881
[TBL] [Abstract][Full Text] [Related]
16. Diffusion-weighted magnetic resonance imaging for the prediction of pathologic response to neoadjuvant chemoradiotherapy in esophageal cancer.
van Rossum PS; van Lier AL; van Vulpen M; Reerink O; Lagendijk JJ; Lin SH; van Hillegersberg R; Ruurda JP; Meijer GJ; Lips IM
Radiother Oncol; 2015 May; 115(2):163-70. PubMed ID: 26002307
[TBL] [Abstract][Full Text] [Related]
17. Impact of neoadjuvant chemoradiation on lymph node status in esophageal cancer: post hoc analysis of a randomized controlled trial.
Robb WB; Dahan L; Mornex F; Maillard E; Thomas PA; Meunier B; Boige V; Pezet D; Le Brun-Ly V; Bosset JF; Mabrut JY; Triboulet JP; Bedenne L; Seitz JF; Mariette C;
Ann Surg; 2015 May; 261(5):902-8. PubMed ID: 25361220
[TBL] [Abstract][Full Text] [Related]
18. Dose escalated neoadjuvant chemoradiotherapy with dose-painting intensity-modulated radiation therapy and improved pathologic complete response in locally advanced esophageal cancer.
Venkat PS; Shridhar R; Naghavi AO; Hoffe SE; Almhanna K; Pimiento JM; Fontaine JP; Abuodeh Y; Meredith KL; Frakes JM
Dis Esophagus; 2017 Jul; 30(7):1-9. PubMed ID: 30052899
[TBL] [Abstract][Full Text] [Related]
19. Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy?
Chadha AS; Liu G; Chen HC; Das P; Minsky BD; Mahmood U; Delclos ME; Suh Y; Sawakuchi GO; Beddar S; Katz MH; Fleming JB; Javle MM; Varadhachary GR; Wolff RA; Crane CH; Wang X; Thames H; Krishnan S
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):323-332. PubMed ID: 28068240
[TBL] [Abstract][Full Text] [Related]
20. The Use of Trimodality Treatment in Patients With Locally Advanced Oesophageal Squamous Cell Carcinoma: An Experience From a Large Cancer Centre in Pakistan.
Qamar MFU; Hanif H; Haider I; Khaleeq N; Misbah D; Inam Y; Anjum M
Cureus; 2023 Oct; 15(10):e47835. PubMed ID: 38021746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
